Novartis phase III trial for next-generation malaria treatment KLU156 meets primary endpoint, with potential to combat antimalarial resistance: Basel Friday, November 14, 2025, 09 ...

A new drug called GanLum and a combination of four existing medications have been cited as potential options to treat this ...

As it presented final-stage trial results, Novartis said the new antimalarial drug it is developing is as effective as existing treatments and could help tackle rising drug resistance. The drug, ...

Novartis' GanLum met key Phase 3 goals, showing strong efficacy and safety in malaria patients, including against resistant ...

A promising new malaria drug shows incredible promise in fighting resistance and could save thousands of lives.

16 January 2025 A district court of appeal has paused MSN Pharmaceuticals’ launch | Result comes days after the Federal ...

Neurvati Neurosciences, the neuroscience development platform of Blackstone Life Sciences, appointed Carlos Martin as Chief ...

Read more from STAT’s Chelsea Cirruzzo and Daniel Payne for more details on what Vance had to say and what attendees received ...

Novartis (NVS) stock is in focus as the company announces a late-stage trial win for its new malaria drug GanLum developed ...

This episode of Pharma Pulse discusses how Dr. Richard Pazdur’s appointment signals a new era for FDA drug evaluation, why hospitals are opposing the government’s 340B pilot program, and how Novartis ...

In 2022, the WHO hailed Novartis’ GanLum as the most promising non-artemisinin-based combination. The Swiss drugmaker ...

Researchers are reporting two promising approaches to counteract malaria's growing drug resistance. Switzerland-based ...